1stOncology™: Cancer Intelligence Service – Page 14360 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Polaris Group Announces Treatment of First Patient in a Phase 2 Study of ADI?PEG 20 Plus Gemcitabine and Docetaxel for Soft Tissue Sarcoma

On May 31, 2018 Polaris Group reported that the first patient has been dosed in a phase 2 trial of ADI‑PEG 20 in combination with gemcitabine and docetaxel for the treatment of soft tissue sarcoma, sponsored by Washington University (Press release, Polaris Pharmaceuticals, MAY 31, 2018, View Source [SID1234527003]). In addition to a global phase 2/3 study in malignant plural mesothelioma featuring ADI‑PEG 20 in combination with pemetrexed and cisplatin and a global phase 2 study in hepatocellular carcinoma featuring ADI‑PEG 20 in combination with FOLFOX, Polaris Group is currently conducting multiple phase 1 clinical trials, including ADI‑PEG 20 in combination with pembrolizumab in solid tumors, in combination with low dose cytarabine for acute myeloid leukemia in older patients, and in combination with atezolizumab, pemetrexed and cisplatin in non-small cell lung carcinoma.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

"We are very excited to partner with Polaris to bring metabolic therapies to the field of rare tumors", said the lead investigator Brian Van Tine, M.D., Ph.D., Associate Professor of Medicine and Sarcoma Program Director at Barnes and Jewish Hospital, Washington University in St. Louis.

About ADI-PEG 20

ADI‑PEG 20 is a biologic being developed by Polaris Group to treat cancers carrying a major metabolic defect that renders them unable to internally synthesize arginine. Because arginine is essential for protein synthesis and survival of cells, these cancer cells become dependent upon the external supply of arginine to survive and grow. ADI‑PEG 20 is designed to deplete the external supply of arginine, causing arginine-dependent cancer cells to die while leaving the patient’s normal cells unharmed. Multiple cancers have been reported to have a high degree of arginine-dependency and can potentially be treated with ADI‑PEG 20.

Pacira Pharmaceuticals to Present at the Jefferies 2018 Healthcare Conference

On May 31, 2018 Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) reported that Dave Stack, chairman and chief executive officer, will present at the Jefferies 2018 Healthcare Conference at 9:30 AM ET on Tuesday, June 5, 2018 (Press release, Pacira Pharmaceuticals, MAY 31, 2018, View Source;p=RssLanding&cat=news&id=2352482 [SID1234527001]). Live audio of the presentation can be accessed by visiting the "Events" page of the company’s website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.

Myriad Genetics to Present at Two Upcoming Investor Conferences

On May 31, 2018 Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, reported that it will be presenting at two upcoming investor conferences (Press release, Myriad Genetics, MAY 31, 2018, View Source [SID1234527000]).

On June 12, 2018, Mark C. Capone, president and CEO, will present at the 39th Annual Goldman Sachs Healthcare Conference in Palos Verdes, California at 4:00 p.m. ET.

On June 13, 2018, R. Bryan Riggsbee, chief financial officer, will present at the William Blair 38th Annual Growth Stock Conference in Chicago, Illinois at 3:40 p.m. ET.

The presentations will be available to interested parties through a live audio webcast accessible through a link in the investor information section of Myriad’s website at www.myriad.com.

Molecular Templates to Present at the Jefferies Global Healthcare Conference

On May 31, 2018 Molecular Templates, Inc. (Nasdaq:MTEM) ("Molecular"), a clinical-stage oncology company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer, reported that its management will provide a corporate overview at the Jefferies Global Healthcare Conference, taking place June 5-8 at the Grand Hyatt New York hotel in New York City (Press release, Molecular Templates, MAY 31, 2018, View Source [SID1234526999]).

Presentation Details
Date:
Time:
Webcast: Thursday, June 7
8:30am Eastern Time
View Source

Mirati To Present New Data In Renal Cell Carcinoma From Ongoing Phase 1b Clinical Trial Of Single Agent Sitravatinib At The 2018 ASCO Annual Meeting

On May 31, 2018 Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, reported that new data from the ongoing Phase 1b clinical trial of single agent sitravatinib will be presented at the 2018 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting to be held June 1-5, 2018 in Chicago (Press release, Mirati, MAY 31, 2018, View Source [SID1234526998]). The data will highlight initial results from the cohort evaluating sitravatinib in the treatment of patients with metastatic renal cell carcinoma (mRCC) who are refractory to anti-angiogenic therapy.

"These results demonstrate that sitravatinib is active as a single agent in the treatment of patients with refractory mRCC," said Charles M. Baum, M.D., Ph.D., President and Chief Executive Officer. "We believe that the single agent data provide further rationale for the combination of sitravatinib with checkpoint inhibitor therapy for the treatment of mRCC. Our strategic partner, BeiGene, Ltd., intends to evaluate the combination of sitravatinib and the anti-PD-1 checkpoint inhibitor, tislelizumab, in patients with mRCC following dose and schedule confirmation, that is anticipated to begin later this year."

Title: Evaluation of the Spectrum Selective RTK Inhibitor Sitravatinib in Clear Cell Renal Cell Carcinoma (ccRCC) Refractory to Anti-Angiogenic Therapy
Presentation Date and Time: Saturday, June 2, 2018, 8:00 a.m. – 11:30 a.m. CST
Abstract Number: 4568
Poster Board: 394
Session Title: Genitourinary (Non-prostate) Cancer
Location: Hall A

About Sitravatinib

Sitravatinib is a spectrum-selective kinase inhibitor that potently inhibits receptor tyrosine kinases (RTKs), including TAM family receptors (TYRO3, Axl, Mer), split family receptors (VEGFR2, KIT) and RET. As an immuno-oncology agent, sitravatinib is being tested in combination with nivolumab (OPDIVO), an anti-PD-1 checkpoint inhibitor, in NSCLC patients who have experienced documented disease progression following treatment with a checkpoint inhibitor. Sitravatinib’s potent inhibition of TAM and split family RTKs may overcome resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment, enhancing antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation.

Sitravatinib is also being evaluated as a single agent in a Phase 1b expansion trial enrolling patients whose tumors harbor CBL, CHR4Q12 and RET genetic alterations in NSCLC and other solid tumors.